We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Sorafenib is recommended for the first-line treatment of advanced hepatocellular carcinoma (HCC). However, the median progression-free survival (PFS) of patients with HCC and major portal vein tumor(More)
  • 1